Emergent Biosolutions
(EBS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Sales | 164,300 | 327,400 | 239,900 | 242,700 | 307,500 |
| Cost of Goods | 152,900 | 220,200 | 147,200 | 169,800 | 155,900 |
| Gross Profit | 11,400 | 107,200 | 92,700 | 72,900 | 151,600 |
| Operating Expenses | 159,900 | 166,500 | 138,200 | 145,700 | 146,100 |
| Operating Income | -147,600 | -59,100 | -45,300 | -72,000 | 6,400 |
| Interest Expense | 17,900 | 12,800 | 8,500 | 7,800 | 8,200 |
| Other Income | 4,900 | 6,700 | -13,400 | -3,000 | -2,000 |
| Pre-tax Income | -160,600 | -65,200 | -67,200 | -82,800 | -3,800 |
| Income Tax | 25,600 | -800 | 19,900 | -26,400 | -100 |
| Net Income Continuous | -186,200 | -64,400 | -87,100 | -56,400 | -3,700 |
| Net Income | $-186,200 | $-64,400 | $-87,100 | $-56,400 | $-3,700 |
| EPS Basic Total Ops | -3.71 | -1.27 | -1.75 | -1.13 | -0.07 |
| EPS Basic Continuous Ops | -3.71 | -1.28 | -1.75 | -1.13 | -0.07 |
| EPS Diluted Total Ops | -3.71 | -1.27 | -1.75 | -1.13 | -0.07 |
| EPS Diluted Continuous Ops | -3.71 | -1.28 | -1.75 | -1.13 | -0.07 |
| EBITDA(a) | $-112,000 | $-15,700 | $-12,000 | $-26,500 | $38,300 |